The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Nexalin Technology Secures US Patent for Deep-Brain Stimulation Targeting Insomnia | 5 | 7 | 29-06-2026 |
| 2 | Apnimed Appoints New CEO as Investigational OSA Therapy Nears FDA Decision | 0 | 5 | 22-06-2026 |
| 3 | Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe | 0 | 5 | 16-06-2026 |
| 4 | Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments | 2 | 6 | 24-06-2026 |
| 5 | Health Canada Approves Zepbound for OSA in Adults With Obesity | 5 | 8 | 25-06-2026 |
| 6 | Lilly’s Investigational Triple Agonist Retatrutide Reduces OSA Severity in Phase 3 Trial | 6 | 7 | 23-06-2026 |
| 7 | New Pivotal Study Data Released for Takeda’s Oveporexton | 5 | 7 | 16-06-2026 |
| 8 | Ognomy Sleep Secures $20M Series A to Expand AI-Enabled Sleep Apnea Care | 5 | 7 | 01-07-2026 |
| 9 | Bryggs Medical Launches ULTepap 2 with Adjustable Pressure Settings | 0 | 5 | 06-07-2026 |
| 10 | OxiWear Secures Payor Coverage for Continuous Oxygen Measuring Wearable | 5 | 7 | 19-06-2026 |